369 related articles for article (PubMed ID: 28296674)
1. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.
Wen H; Hockenberry JM; Borders TF; Druss BG
Med Care; 2017 Apr; 55(4):336-341. PubMed ID: 28296674
[TBL] [Abstract][Full Text] [Related]
2. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
Wen H; Hockenberry JM; Pollack HA
JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
[TBL] [Abstract][Full Text] [Related]
3. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
Soper R; Appajosyula S; Deximo C
Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine Prescribing and Challenges Faced Among National Health Service Corps Clinicians.
Rowan K; Shah SV; Binns S; Murphy E; Satorius J; Ghobadi A; Krauss D; Robbins C; Schoebel V; Knudson A; Kepley H;
JAMA Netw Open; 2024 May; 7(5):e2411742. PubMed ID: 38758556
[TBL] [Abstract][Full Text] [Related]
6. Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018.
Barenie RE; Sinha MS; Kesselheim AS
Value Health; 2021 Feb; 24(2):182-187. PubMed ID: 33518024
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
Jones CM; McCance-Katz EF
Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
[TBL] [Abstract][Full Text] [Related]
8. The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.
Knudsen HK; Hartman J; Walsh SL
Drug Alcohol Depend; 2022 Mar; 232():109336. PubMed ID: 35123365
[TBL] [Abstract][Full Text] [Related]
9. States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.
Knudsen HK; Lofwall MR; Havens JR; Walsh SL
Drug Alcohol Depend; 2015 Dec; 157():36-43. PubMed ID: 26483356
[TBL] [Abstract][Full Text] [Related]
10. Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US.
Stein BD; Saloner B; Schuler MS; Gurvey J; Sorbero M; Gordon AJ
JAMA; 2021 Jun; 325(21):2206-2208. PubMed ID: 34061152
[TBL] [Abstract][Full Text] [Related]
11. Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.
Knudsen HK; Studts JL
J Behav Health Serv Res; 2019 Jan; 46(1):151-163. PubMed ID: 30069622
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients.
Abraham R; Wilkinson E; Jabbarpour Y; Petterson S; Bazemore A
J Am Board Fam Med; 2020; 33(1):9-16. PubMed ID: 31907241
[TBL] [Abstract][Full Text] [Related]
13. Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
Qian J; Khatiwada AP; Xue X
Am J Addict; 2024 May; 33(3):335-338. PubMed ID: 38069608
[TBL] [Abstract][Full Text] [Related]
14. Prescription opioid use patterns, use disorder diagnoses and addiction treatment receipt after the 2014 Medicaid expansion in Oregon.
Springer R; Marino M; Bailey SR; Angier H; O'Malley JP; Hoopes M; Lindner S; DeVoe JE; Huguet N
Addiction; 2019 Oct; 114(10):1775-1784. PubMed ID: 31106483
[TBL] [Abstract][Full Text] [Related]
15. Rise and regional disparities in buprenorphine utilization in the United States.
Pashmineh Azar AR; Cruz-Mullane A; Podd JC; Lam WS; Kaleem SH; Lockard LB; Mandel MR; Chung DY; Simoyan OM; Davis CS; Nichols SD; McCall KL; Piper BJ
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):708-715. PubMed ID: 32173955
[TBL] [Abstract][Full Text] [Related]
16. Impact of Medicaid Expansion on Access to Opioid Analgesic Medications and Medication-Assisted Treatment.
Sharp A; Jones A; Sherwood J; Kutsa O; Honermann B; Millett G
Am J Public Health; 2018 May; 108(5):642-648. PubMed ID: 29565661
[TBL] [Abstract][Full Text] [Related]
17. U.S. Survey of factors associated with adherence to standard of care in treating pregnant women with opioid use disorder.
Howard HG; Freeman K
J Psychosom Obstet Gynaecol; 2020 Mar; 41(1):74-81. PubMed ID: 31244358
[No Abstract] [Full Text] [Related]
18. Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic.
Nguyen TD; Gupta S; Ziedan E; Simon KI; Alexander GC; Saloner B; Stein BD
JAMA Intern Med; 2021 Apr; 181(4):562-565. PubMed ID: 33346795
[TBL] [Abstract][Full Text] [Related]
19. Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers.
Knudsen HK; Lofwall MR; Walsh SL; Havens JR; Studts JL
J Addict Med; 2018; 12(1):31-39. PubMed ID: 28914663
[TBL] [Abstract][Full Text] [Related]
20. Underused Weapon In the War on Addiction.
Kelley T
Manag Care; 2018 Jan; 27(1):15-17. PubMed ID: 29369763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
